Healthcare & Pharmaceuticals

Relying on J&J's analyses to assess vaccine booster dose data -U.S. FDA staff

1 minute read

A vial of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine is seen during a vaccination event hosted by Miami - Dade County and Miami Heat, at FTX Arena in Miami, Florida, U.S., August 5, 2021. REUTERS/Marco Bello

Oct 13 (Reuters) - U.S. Food and Drug Administration scientists said on Wednesday they did not have time to analyze data submitted by Johnson & Johnson (JNJ.N) on a booster dose of its single-dose COVID-19 vaccine, in a rare case where the agency relied on a company's analyses to brief its advisory panel.

An outside panel of experts will meet on Friday to discuss whether a booster dose of J&J's vaccine is safe and effective anywhere between two months and six months after taking the original dose.

Register now for FREE unlimited access to Reuters.com
Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters